Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Zhengye Biotechnology Holding's Debt-to-EBITDA or its related term are showing as below:
ZYBT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.78 Med: 0.76 Max: 2.03
Current: -1.78
During the past 5 years, the highest Debt-to-EBITDA Ratio of Zhengye Biotechnology Holding was 2.03. The lowest was -1.78. And the median was 0.76.
ZYBT's Debt-to-EBITDA is ranked worse than 100% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs ZYBT: -1.78
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Zhengye Biotechnology Holding Debt-to-EBITDA Related Terms
Zhengye Biotechnology Holding Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYBT vs TLPH, CPHI, CPIX: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Zhengye Biotechnology Holding (ZYBT) has a Debt-to-EBITDA of -1.47 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zhengye Biotechnology Holding. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is Zhengye Biotechnology Holding's Debt-to-EBITDA too high?
Zhengye Biotechnology Holding's current Debt-to-EBITDA is -1.47. Based on the distribution chart, Zhengye Biotechnology Holding ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Debt-to-EBITDA compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #999999 out of 685 companies for Debt-to-EBITDA. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median Debt-to-EBITDA is 1.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zhengye Biotechnology Holding. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current Debt-to-EBITDA is -1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Debt-to-EBITDA of -1.47. The current Debt-to-EBITDA is -1.47. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Debt-to-EBITDA is -1.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
